Actavis acquired Warner Chilcott in a stock-for-stock transaction valued at approximately $8.5 billion, creating Actavis plc, an Ireland-domiciled specialty pharmaceutical company with roughly $11 billion in pro forma revenue. The transaction established the Irish tax-inversion structure later used for the Forest Laboratories acquisition.